Literature DB >> 11569536

Cellular basis of steroid neuroprotection in the wobbler mouse, a genetic model of motoneuron disease.

M C González Deniselle1, S L González, A F De Nicola.   

Abstract

1. The Wobbler mouse suffers an autosomal recessive mutation producing severe motoneuron degeneration and astrogliosis in the spinal cord. It has been considered a suitable model of human motoneuron disease, including the sporadic form of amyotrophic lateral sclerosis (ALS). 2. Evidences exist demonstrating increased oxidative stress in the spinal cord of Wobbler mice, whereas antioxidant therapy delayed neurodegeneration and improved muscle trophism. 21-Aminosteroids are glucocorticoid-derived hydrophobic compounds with antioxidant potency 3 times higher than vitamin E and 100 times higher than methylprednisolone. They do not bind to intracellular receptors, and prevent lipid peroxidation by insertion into membrane lipid bilayers. 3. In common with the spinal cord of ALS patients, Wobbler mice present astrocytosis with hyperexpression of glial fibrillary acidic protein (GFAP), and increased expression of nitric oxide synthase (NOS) and growth-associated protein (GAP-43) in motoneurons. Here, we review our studies on the effects of a 21-aminosteroid on GFAP, NOS, and GAP-43. 4. First, we showed that 21-aminosteroid treatment further increased GFAP-expressing astrocytes in gray matter of the Wobbler spinal cord. This effect may provide neuroprotection if one considers a trophic and beneficial function of astrocytes during the course of degeneration. Other neuroprotectans used in Wobbler mice (T-588) also increased pre-existing astrocytosis. 5. Second, histochemical determination of NADPH-diaphorase, a parameter indicative of neuronal NOS activity, showed that the 21-aminosteroid down-regulated the high activity of this enzyme in ventral horn motoneurons. Therefore, suppression of nitric oxide by decreasing NADPH-diaphorase (NOS) activity may provide neuroprotection considering that excess NO is highly toxic to motoneurons. 6. Finally, 21-aminosteroid treatment significantly attenuated the aberrant expression of both GAP-43 protein and mRNA in Wobbler motoneurons. Hyperexpression of GAP-43 possibly indicated abnormal synaptogenesis, denervation, and muscle atrophy, parameters which may return to normal following antioxidant steroid treatment. 7. Besides 21-aminosteroids, other steroids also behave as neuroprotectans. In this regard, degenerative diseases may constitute potential targets of these hormones, based on the fact that the spinal cord expresses in a regional and cell-specific fashion, receptors for androgens. progesterone, adrenal steroids, and estrogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11569536     DOI: 10.1023/a:1010943104315

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  65 in total

Review 1.  Role of neurotrophic factors in neuronal development.

Authors:  C E Henderson
Journal:  Curr Opin Neurobiol       Date:  1996-02       Impact factor: 6.627

Review 2.  The neuroprotective pharmacology of methylprednisolone.

Authors:  E D Hall
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

3.  Reduced branching and length of dendrites detected in cervical spinal cord motoneurons of Wobbler mouse, a model for inherited motoneuron disease.

Authors:  W Y Ma; L L Vacca-Galloway
Journal:  J Comp Neurol       Date:  1991-09-08       Impact factor: 3.215

Review 4.  GAP-43: an intrinsic determinant of neuronal development and plasticity.

Authors:  L I Benowitz; A Routtenberg
Journal:  Trends Neurosci       Date:  1997-02       Impact factor: 13.837

5.  Protective effect of a novel free radical scavenger, OPC-14117, on wobbler mouse motor neuron disease.

Authors:  K Abe; S Morita; T Kikuchi; Y Itoyama
Journal:  J Neurosci Res       Date:  1997-04-01       Impact factor: 4.164

6.  Murine motor neuron disease (the wobbler mouse): degeneration and regeneration of the lower motor neuron.

Authors:  H Mitsumoto; W G Bradley
Journal:  Brain       Date:  1982-12       Impact factor: 13.501

7.  The effects of two 21-aminosteroids on overt infarct size 48 hours after middle cerebral artery occlusion in the rat.

Authors:  T Beck; G W Bielenberg
Journal:  Brain Res       Date:  1991-09-27       Impact factor: 3.252

8.  Impaired slow axonal transport in wobbler mouse motor neuron disease.

Authors:  H Mitsumoto; P Gambetti
Journal:  Ann Neurol       Date:  1986-01       Impact factor: 10.422

Review 9.  Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors.

Authors:  N J Laping; B Teter; N R Nichols; I Rozovsky; C E Finch
Journal:  Brain Pathol       Date:  1994-07       Impact factor: 6.508

10.  Abnormal astrocyte differentiation and defective cellular interactions in wobbler mouse spinal cord.

Authors:  D Hantaz-Ambroise; B Blondet; M Murawsky; F Rieger
Journal:  J Neurocytol       Date:  1994-03
View more
  4 in total

1.  S100B protein and 4-hydroxynonenal in the spinal cord of wobbler mice.

Authors:  Valentina Corvino; Rita Businaro; Maria Concetta Geloso; Paolo Bigini; Valentina Cavallo; Elena Pompili; Tiziana Mennini; Lorenzo Fumagalli; Fabrizio Michetti
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

Review 2.  Developmental and Functional Effects of Steroid Hormones on the Neuroendocrine Axis and Spinal Cord.

Authors:  L Zubeldia-Brenner; C E Roselli; S E Recabarren; M C Gonzalez Deniselle; H E Lara
Journal:  J Neuroendocrinol       Date:  2016-07       Impact factor: 3.627

Review 3.  Progesterone receptors: form and function in brain.

Authors:  Roberta Diaz Brinton; Richard F Thompson; Michael R Foy; Michel Baudry; Junming Wang; Caleb E Finch; Todd E Morgan; Christian J Pike; Wendy J Mack; Frank Z Stanczyk; Jon Nilsen
Journal:  Front Neuroendocrinol       Date:  2008-02-23       Impact factor: 8.606

4.  CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis.

Authors:  Matthew C Evans; Pieter J Gaillard; Marco de Boer; Chantal Appeldoorn; Rick Dorland; Nicola R Sibson; Martin R Turner; Daniel C Anthony; Helen B Stolp
Journal:  Acta Neuropathol Commun       Date:  2014-06-13       Impact factor: 7.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.